Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization

Journal of Virology

Volumn 84, Issue 1, 2010, Pages 630-638

  Cheng, Cheng ^a   Gall, Jason G D ^b   Nason, Martha ^a   King, C Richter ^b,g   Koup, Richard A ^a   Roederer, Mario ^a   McElrath, M Juliana ^c   Morgan, Cecilia A ^c   Churchyard, Gavin ^d   Baden, Lindsey R ^e   Duerr, Ann C ^c   Keefer, Michael C ^f   Graham, Barney S ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENVEC INC   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d AURUM INSTITUTE   (South Africa)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS TYPE 5 NEUTRALIZING ANTIBODY; ADENOVIRUS VECTOR; CAPSID PROTEIN; CROSS REACTING ANTIBODY; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HVTN 204; NEUTRALIZING ANTIBODY; PLACEBO; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN A; VIRUS ENVELOPE PROTEIN B; VIRUS ENVELOPE PROTEIN C; VRC 006;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS FIBER; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; EPITOPES; GENE PRODUCTS, GAG; GENETIC VECTORS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNIZATION;

HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 72849119268     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00866-09     Document Type: Article

References (22)

1. Arrode, G., R. Hegde, Y. Jin, D. K. Singh, O. Narayan, and Y. Chebloune. 2008. Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine. Vaccine 26:3795-3804.
2. Brough, D. E., A. Lizonova, C. Hsu, V. A. Kulesa, and I. Kovesdi. 1996. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70:6497-6501.
3. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
4. Catanzaro, A. T., R. A. Koup, M. Roederer, R. T. Bailer, M. E. Enama, Z. Moodie, L. Gu, J. E. Martin, L. Novik, B. K. Chakrabarti, B. T. Butman, J. G. Gall, C. R. King, C. A. Andrews, R. Sheets, P. L. Gomez, J. R. Mascola, G. J. Nabel, and B. S. Graham. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194:1638-1649.
5. Cheng, C., J. G. Gall, W. P. Kong, R. L. Sheets, P. L. Gomez, C. R. King, and G. J. Nabel. 2007. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3:e25.
6. Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian, and J. Wilson. 1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1574-1583. (Pubitemid 29465516)
7. Gahéry-Ségard, H., F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J. G. Guillet. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72:2388-2397. (Pubitemid 28100799)
8. Hamilton, M. M., G. A. Byrnes, J. G. Gall, D. E. Brough, C. R. King, and L. L. Wei. 2008. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol. Vis. 14:2535-2546.
9. Hanke, T. 2008. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7:303-309.
10. Hong, S. S., N. A. Habib, L. Franqueville, S. Jensen, and P. A. Boulanger. 2003. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375.
11. Lemiale, F., H. Haddada, G. J. Nabel, D. E. Brough, C. R. King, and J. G. Gall. 2007. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25:2074-2084. (Pubitemid 46227670)
12. Moore, J. P., P. J. Klasse, M. J. Dolan, and S. K. Ahuja. 2008. AIDS/HIV. A STEP into darkness or light? Science 320:753-755.
13. Nwanegbo, E., E. Vardas, W. Gao, H. Whittle, H. Sun, D. Rowe, P. D. Robbins, and A. Gambotto. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
14. Priddy, F. H., D. Brown, J. Kublin, K. Monahan, D. P. Wright, J. Lalezari, S. Santiago, M. Marmor, M. Lally, R. M. Novak, S. J. Brown, P. Kulkarni, S. A. Dubey, L. S. Kierstead, D. R. Casimiro, R. Mogg, M. J. DiNubile, J. W. Shiver, R. Y. Leavitt, M. N. Robertson, D. V. Mehrotra, and E. Quirk. 2008. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46:1769-1781.
15. Shenk, T. E. 2001. Adenoviridae: the viruses and their replication, p. 2265- 2300. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
16. Shiver, J. W., and E. A. Emini. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:355-372.
17. Sprangers, M. C., W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. Havenga, and S. Kostense. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41:5046-5052.
18. Sumida, S. M., D. M. Truitt, A. A. Lemckert, R. Vogels, J. H. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, S. S. Jackson, D. A. Gorgone, M. A. Lifton, M. Essex, B. D. Walker, J. Goudsmit, M. J. Havenga, and D. H. Barouch. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185.
19. Thorner, A. R., R. Vogels, J. Kaspers, G. J. Weverling, L. Holterman, A. A. Lemckert, A. Dilraj, L. M. McNally, P. M. Jeena, S. Jepsen, P. Abbink, A. Nanda, P. E. Swanson, A. T. Bates, K. L. O'Brien, M. J. Havenga, J. Goudsmit, and D. H. Barouch. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44:3781-3783.
20. Waddington, S. N., J. H. McVey, D. Bhella, A. L. Parker, K. Barker, H. Atoda, R. Pink, S. M. Buckley, J. A. Greig, L. Denby, J. Custers, T. Morita, I. M. Francischetti, R. Q. Monteiro, D. H. Barouch, N. van Rooijen, C. Napoli, M. J. Havenga, S. A. Nicklin, and A. H. Baker. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
21. Watkins, D. I., D. R. Burton, E. G. Kallas, J. P. Moore, and W. C. Koff. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14:617-621.
22. Wohlfart, C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328. (Pubitemid 18156580)